Exhibit 99.2

KNOXVILLE,  Tenn., April 4 /PRNewswire-FirstCall/  -- Provectus  Pharmaceuticals
Inc. (OTC Bulletin  Board:  PVCT - News), an innovative  pharmaceutical  company
engaged  in the  research  and  development  of  breakthrough  technologies  for
psoriasis,  breast  cancer and other  serious  diseases,  announced  that it has
retired its existing  convertible debt instrument with Cornell Capital Partners,
LP, and that the standby  equity line in place with Cornell has been  cancelled.
Retiring  the  convertible  debt and  canceling  the  equity  line will have the
cumulative effect of canceling 4.3 million unissued registered shares.

Provectus CEO Dr. Craig Dees commented, "There are numerous benefits to retiring
this  existing  debt  instrument,  including  the  elimination  of an adjustable
conversion price and the limitation of potential future dilution.  The canceling
of the equity line further limits potential future dilution.  We very much value
Cornell's assistance and confidence as an investor during the past year."

About Provectus Pharmaceuticals Inc.

Provectus  Pharmaceuticals Inc. is a pioneering  pharmaceutical company actively
engaged in the design, development and marketing of pharmaceutical  technologies
for the treatment of liver, breast and prostate cancer and metastatic  melanoma.
In addition,  Provectus is developing  treatments for chronic skin diseases such
as psoriasis.

Provectus' patented approach targets abnormal or diseased cells in its design of
treatments for dermatological diseases, in particular,  chronic, severe cases of
psoriasis and eczema.  Clinical studies are already in process for the Company's
topical agent Xantryl(TM).

In  addition,  certain  skin cancers may be targeted and treated more safely and
effectively   using   Xantryl(TM).   Although  still  in  the  early  stages  of
development,  pre-clinical  studies have shown that Provecta(TM),  when injected
directly  into a tumor,  not only kills the  treated  tumor but also may protect
against its spreading throughout the body.

The  Company's  offices and  laboratory  are located at 7327 Oak Ridge  Highway,
Suite A, Knoxville,  TN 37931;  telephone:  865 769 4011. For more  information,
contact  the  Company  at   info@pvct.com  or  visit  the  corporate  Web  site:
http://www.pvct.com .

Forward-looking Statement

This  release  and  others  statements  issued  or made from time to time by the
company or its  representatives  contain  comments that may constitute  forward-
looking  statements.  Those include statements  regarding the intent,  belief or
current expectations of the company and members of its management teams, as well
as the assumptions on which the statements are based.  Prospective investors are
cautioned  that such  forward-looking  statements  are not  guarantees of future
performance  and involve risks and  uncertainties,  and that actual  results may
differ materially from those contemplated by such forward- looking statements.

- --------------------------------------
Source: Provectus Pharmaceuticals Inc.